BRIEF-Regeneron Announces Strategic Collaboration With Parabilis Medicines To Advance Novel Antibody-Helicon Conjugates Across Multiple Therapeutic Areas

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

REGN

0.00

May 18 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:

  • REGENERON ANNOUNCES STRATEGIC COLLABORATION WITH PARABILIS MEDICINES TO ADVANCE NOVEL ANTIBODY-HELICON™ CONJUGATES ACROSS MULTIPLE THERAPEUTIC AREAS

  • REGENERON PHARMACEUTICALS INC: AGREEMENT PROVIDES FOR PARABILIS TO RECEIVE $125M FROM REGENERON

  • REGENERON: DEAL INCLUDES ABOUT $2.2B IN ADDITIONAL POTENTIAL MILESTONE PAYMENTS PLUS TIERED ROYALTIES

  • REGENERON PHARMACEUTICALS: UNDER TERMS, ADDITIONAL TARGETS MAY BE PURSUED UPON ADDITIONAL OPTION PAYMENTS FROM CO

Source text: ID:nGNX5zPMMr

Further company coverage: REGN.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.